Evidence map›Paper›PMID 40790333›Full record

ArticleScientific reports2025

Anti-protein arginine methyltransferase 5 (PRMT5) antibodies is associated with interstitial lung disease in rheumatoid arthritis.

Renliang Huang, Jiaxi Guo, Qiaomiao Zhou, Heqing Huang, Shaowei Lin, Yikai Lin, Frank Petersen, Xinhua Yu, Aiping Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Renliang Huang *Department of Genetics and Prenatal Diagnosis, Hainan Women and Children's Medical Center, Haikou, Hainan, China.
Jiaxi Guo *Department of Respiratory and Critical Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, NO.55 ZhenHai Road, Xiamen, 361001, China.
Qiaomiao ZhouDepartment of Genetics and Prenatal Diagnosis, Hainan Women and Children's Medical Center, Haikou, Hainan, China.
Heqing HuangDepartment of Rheumatology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Shaowei LinDepartment of Nuclear Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Yikai LinDepartment of Radiology, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, China.
Frank PetersenPriority Area Chronic Lung Diseases, Research Center Borstel-Leibniz Lung Center, Member of the German Center for Lung Research (DZL), 23845, Borstel, Germany.
Xinhua YuDepartment of Genetics and Prenatal Diagnosis, Hainan Women and Children's Medical Center, Haikou, Hainan, China. xinhuayu@fz-borstel.de.
Aiping MaDepartment of Respiratory and Critical Medicine, School of Medicine, The First Affiliated Hospital of Xiamen University, Xiamen University, NO.55 ZhenHai Road, Xiamen, 361001, China. aiping.ma@xmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, anti-protein arginine methyltransferase 5 (PRMT5) antibodies has been identified a novel marker for systemic sclerosis (SSc). The present study aimed to to explore the association between anti-PRMT5 antibodies and rheumatoid arthritis (RA). The study recruited a cohort of 33 patients diagnosed with SSc, 87 patients with RA, and 31 healthy control subjects. Serum levels of the anti-PRMT5 antibodies were measured using a double-antigen sandwich enzyme-linked immunosorbent assay (ELISA). Patients with SSc exhibited higher serum levels (p < 0.001) and seropositivity rates (48.5% vs. 0%, p < 0.0001) of anti-PRMT5 antibodies compared to healthy subjects. Notably, serum levels of anti-PRMT5 antibodies were significantly elevated in patients with RA compared to healthy controls (p < 0.001), with a corresponding increase in the rate of seropositivity (14.9% vs. 0%, p < 0.05). Receiver operating curve analysis for anti-PRMT5 antibody levels yielded area under the curve values of 0.768 for distinguishing RA patients from healthy controls, and 0.903 for distinguishing SSc patients from controls. Furthermore, elevated levels of anti-PRMT5 antibodies were significantly associated with the presence of interstitial lung disease (ILD) (p < 0.0001) and antinuclear antibody positivity (p < 0.01). This study not only confirms the association of the anti-PRMT5 antibodies with SSc but also, for the first time, demonstrates a significant association between the anti-PRMT5 antibodies and RA, particularly in the context of RA-associated ILD.

Indexed as

Arthritis, RheumatoidAutoantibodiesLung Diseases, InterstitialProtein-Arginine N-MethyltransferasesAdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedROC CurveScleroderma, SystemicAutoantibodiesBiomarkersPRMT5 protein, humanProtein-Arginine N-MethyltransferasesAnti-PRMT5 antibodiesInterstitial lung diseasesRheumatoid arthritisSystemic sclerosis

Identifiers

PMID40790333
PMCPMC12340103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.